Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CTIX pps action appears to be the inverse of AVxx's. Its a small world after all.
Try 7+ years bought shares at 0.19 to 3.50. It helps not to follow pps everyday. At least I don't have to worry about George Evans anymore!
Unsettled funds is what I was buying new shares with this morning. This must be a flippers nightmare being locked in to the stock for the next 3 trading days. I feel sorry for those that had their stop losses tripped perhaps some of them not knowing it even occurred.
I am a research coordinator at the University of Washington, for the last 15 years. I manage the aquatic labs which is essentially a much larger version of the fish tank section you see at your local petco or petsmart store. Now I am just the "fish guy" but I have 7 principal investigators (PI's) whose work ranges from cancers to birth defects, stem and hair cells etc. They all have traditional scientific labs like the one Leo provided pictures of and I can confirm that is an active lab of moderate to heavy use.
I am not just talking about clutter on the counter tops or the lab coat precariously hanging off the back the chair. More telling is the half-full squirt bottles, styrofoam boxes transporting items from the freezer/frig, notes on the fume hood and other equipment that red tape is usually where you write when it was cleaned last or this button is broken. Reflective material on the glass refrigerators is not stock used when your storing enzymes or chemicals that cannot be exposed to light. I especially like that bucket of "misc. parts/junk" under the workspace -yep that looks familiar to me.
All of my PI's are very busy in their labs with lots of grad. students and postdocs. Some of the PIs maintain there labs at all times as if they were brand new and never used while other PI's have countertops where you have to dig through stuff just to clear a surface and bicycles parked in the back of the lab. YADA YADA YADA that is a real lab.
Probably but you still shouldn't be climbing in to the hot tub. Although it would my best shot at it as well especially since this short attack today.
Well, that was a...well...orchestrated attack.I will give them that but complete BS otherwise. In hinfsight, should have seen this one coming with all new bashers recently showing up on this board.
As far as those pictures go..I say "A shell company! Oh yeah! Then who keeps watering that fake green plastic plant!"
Notice in the picture there is a research poster hanging on the wall in the background next to the open door. I would n't expect to see anyone in the lobby of a research biotech especially at night (light are on timer) He hired an expert!
I temporarily lost some money on this article but I am glad he wrote it because I am still laughing!
Ughhh people what can u do =-)
Dr. Jerry did you give Dr. Menon a Coke-cola by chance?
I am thinking Mean Joe Greene
Prurisol with 10 trial sites and 100 patients should not take too long to complete. Two of the Florida sites are recruiting already.
https://clinicaltrials.gov/ct2/show/NCT02494479?term=prurisol&rank=2
The GovTrial site already lists Recruiting for Prurisol! Yipee
I see Google finance updated the company description on their website.
Description
Cellceutix Corporation (Cellceutix) is a clinical-stage biotechnology company focused on discovering small molecule drugs for diseases, including drug-resistant cancers, psoriasis, autism and inflammatory disease. The Company is focused on developing therapies in oncology, dermatology and antibiotic applications. The Company is also developing pre-clinical compounds for the treatment of diseases, including rheumatoid arthritis, asthma, Lou Gehrig Disease, Parkinson’s disease and multiple sclerosis. The Company’s lead cancer compound, Kevetrin, and other oncology compound is Brilacidin-OM. Prurisol is Cellceutix’s anti-psoriasis drug candidate. Cellceutix’s lead antibiotic compound, Brilacidin, is used for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The Company’s product KM 391 is an Autism compound. The Company’s other pre-clinical candidates include KM 277, KM 278, KM 362, KM-3174 and KM-732.
https://www.google.com/finance?q=OTCMKTS%3ACTIX&ei=KEvAVeHUA4OBiwLnhraoBg
Not many small 300 million biotechs have such a "robust" description.
Wonder how the formulation work is going for hidradenitis suppurativa? Might be some money in pit zits. Ohh come on Leo give us something!
I actually believe that one.
Aspire would not have to file a 13g because CTIX is not on a major exchange being pink or even OTC. How would anyone know if there selling ?
Lets see:
Kevetrin phase 1 wrapping up... with restoration mdm2 pathway and p53. Disappearing spleen lesion, stable stage 4 ovarian cancer orphan drug status. Starting ovarian cancer p2/3, phase 2 in solid tumors and a phase 2 AML (someone else paying). Trial at Harvard. Platform drug
Brilacidin ABSSSI phase 2b results one day treatment equivalent 7 days of the gold-standard billionaire drug Daptomycin. Novel antibiotic that rips the plasma membrane of the bacteria so resistance is futile. QIPD'd a platform drug with anti-inflammatory properties.
Brilacidin-OM currently no effective treatments. Phase 2 underway with expanded trial sites. Brilacidin vs placebo like a Sharknado Nuff Said.
Prurisol- I don't care =-) But phase 2 start or started. Oral psoriasis drug huge market potential.
And a big fat pipeline
Sad attempts at manipulation because you realized stocks go up and down don't belong on this list.
IF we are going to get a comprehensive update? What is Leo waiting on?
He had to PR the Kevetrin Orphan drug status because it came out in to the public realm. I think he felt obligated to disclose Brilacidin ABX end of phase 2 meeting ASAP. Both PR's on these two subject were very brief as if something else was developing, only giving them "lip service" if you will. If it is going to be comprehensive perhaps he is waiting for enrollment in Prurisol or recruitment no#'s from Brilacidin-OM perhaps the wrap up of a Kevetrin cohort? We know there has been a lot of developments that he could inform us about that we already know of clinical sites being added etc. He seems to be waiting on something????
You forgot #11 "The Oxymoron" I just locked in profits on the last run up and dang I cannot figure out why this stock is so undervalued!
Or #12 Why is this stock so undervalued? Too many no# 11's
That was rushed. It was a material company event that fell in to the public domain before CTIX informed shareholders. I guess we cannot say that Leo does not try to give us exciting surprises.
Before applying...they already applied so no 90 days.
Anothdr piece of this buying maybe the slow trickle of the orphan drug status to the media. Each morning I am reading about the same news on different forums.
Thanks SLC, great information there
New PR Out!
The Progressive was a "regular" poster on this some time back. He was on my favorites list but like so many I have not seen on this board for some time.
BINGO! And should help with recruitment rates.
I didn't see any mention of testing subjects for hyper-sensitivity to abacavir only the exclusion criteria:
"History of any allergic reaction to any formulation of abacavir."
They recorded this record just yesterday...good catch.
Lots of trial sites..exciting development
I see Aruda listed as a mutual fund here
http://www.msn.com/en-us/money/stockdetails/ownership/fi-125.1.CTIX.PINX
Don't need a chart to tell you that some investors are anticipating a Monday PR.
Echo i think Brilacidin for diabetic foot is still in its formative stage. CTIX is located in Boston but we have no idea where the trials for it will eventually be.
Please clarify?
We have been range-bound for sometime now ~$2.50 to ~2.75 till news comes. I see no need to get particularly excited when it goes up or down. Looks like Leo is saving up his PR's for a comprehensive update in a week or two. We already know that he has information/developments that he would typically put out in a PR such as additional clinical sites Brilacidin-OM that are now listed FDA clinical trial site. But I believe he is going to try to rocket us to the NASDAQ with a corporate update.
With us coming off/testing the bottom right now ~2.50 I suspect we will go above the high range in the coming days and weeks in anticipation of an update.
I. Thought June was mainly the month for Prurisol, at last.
Well it's been 3weeks since our last PR. I will bet a pretty penny we get one next week. Traders love for PR's will make our Friday Green.
Well you guys do not have to flip. The company could be meeting with the FDA right now. The next interesting PR might come out before mid July.
I think the results of the FDA meeting about Brilacidin ABX could be a significant enough event to get us up over $3 and onto the NASDAQ. Right now we know of the great results from the 2b trial and QIDP from the FDA. But the market as well as Cellceutix made need further guidance i.e. do we get fast track, breakthrough, accelerated approval and/or priority review.
Another big factor is the trial design the FDA and Cellceutix come up with for phase 3. Is it 3000 patients in multiple arms or perhaps 2 phase 3's or much smaller. Safety, cost and everything else goes in to the FDA decisions. The better scenarios are capturing a few of the designations listed above and a smaller phase 3.
Perhaps the market isn't thinking much of Brilacidin until the FDA does. I think the FDA meeting in the next couple weeks here could be one of the biggest catalysts in the companies history and may make the $3's, $4's, and $5's go away.
Dr. Jerry I agree with you. Perhaps we are fortunate that Kevetrin has such a strong safety profile to allow it to be dosed so high that some efficacy can be seen even with the quick clearance if not we may have had to rely on elevated p21 levels at conclusion of the trial. Leo mentioned early on in this trial and several times later on that Kevetrin's future is multi-dose. I am excited to see what happens at these high dose levels especially since we had a disappearing spleen lesion and stable disease with the ovarian patient at lower levels.
Looks like we hit a home run with ovarian cancer in this single regime and should get a few more in a multi-dose phase 2 solid tumors.
Looking at the ASCO poster. The reason cohorts are listed the way they are is because it list the gynecological cancers are first. I believe Gov. was trying to figure out the reasoning for the order in which they are in. Emphasis for sure on gynecological cancers in the presentation. Cohort 8 in particular is interesting not because of the 1 DLT but the fact that 6 of the 7 patients in this 350 mg/m^2 group were in the gynecological cancers.
Hard to detect any other patterns there except to say this group was tested early cohorts 1,2 and tested heavily in cohorts 4,5, and 8.
We sit at 75x the initial dose. First in human yes but what really scuttled progress was the erythema issue around cohort 2,3 and possibly lingered from there on. It wasn't really until cohort 5 that we started to see the bigger dose increases, percent-wise. Not all erythema too figuring grade2ae in stage 4 patients has to be difficult.
What interesting with Brilacidin dosing is what did or didn't happen in its phase 1 trial and what made polymed push so hard in to phase 2a especially since they had Dr. Jorgensen. Polymed collapsed mainly for reasons outside of Brilacidin and oddly Brilacidin couldn't save them. Horrible management..finances and the final blow was Delparantag. Brilacidin wasn't looking to bad coming out of phase 2a.
Just happy to be where were at now.
The most interesting part of the ASCO poster to me is that 205% increase in p21 expression. Dose-dependent p21 expression and Kevetrin has the potential to increase p21 by that much! About a year ago I was trying to figure out if a 10% increase was note worthy it may or may not be but 205, yeah that has to be good. Can't wait to see p21 expression in cohort 10.
In the coming weeks we could have more disappearing lesions and tumors. I was growing impatient with Kevetrin phase 1 now I am rooting for Kevetrin 1500 and another 3 months of dose escalation.
In reflection, the only thing that didn't go great in this trial is the dose escalation particularly early on. Not sure if the CTIX should have pushed harder earlier on especially with the erythema issue but water under the bridge and they followed the standard protocol. We are just now starting to see what Kevetrin can do!
Oh yeah throw in B-ABX, B-OM, Prurisol and all the rest of the pipeline I have never been more excited to be invested here. I suspect we will be uplisted here in the next few weeks. My biggest hope with uplisting is just simply more volume so that a new somewhat fairly valued pps can be vetted.
gynecological cancers any ideas why so many patients here? I know it encompasses many types of cancers but the study still seems heavy in this area. If I were to guess ovarian cancer is our phase 2/3 candidate.
New England Journal of Medicine